ClinicalTrials.gg
CompletedNCT02919501Updated Jun 20, 2018

Study of the Efficacy and Safety of Initial Administration of 17 mg Vortioxetine Intravenously With 10 mg/Day Vortioxetine Orally in Patients With Major Depressive Disorder

A Phase 2 interventional study of Vortioxetine (IV) and Placebo (IV) in Depressive Disorder, Major, sponsored by H. Lundbeck A/S. Completed at 7 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2018-06-20.

Sponsored by H. Lundbeck A/S · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
55
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing vortioxetine in Depressive Disorder, Major — 1 open to participants now, 1 under way, 1 of them phase 3. Vortioxetine · Depressive Disorder, Major.

Enrollment
47th of 54
55 · median 413
Started
2016
with 8 others
Phase 2
6 of 54
none open now
Registered
38th of 54
by date
Lead sponsor
24 of 54
H. Lundbeck A/S

Among the 54 studies testing vortioxetine in Depressive Disorder, Major, this one is the 47th largest by enrollment, is one of 9 that started in 2016, is one of 6 in phase 2, and was the 38th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

1 of the 54 studies testing vortioxetine in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About vortioxetine

Vortioxetine: first FDA approval 2013 (TRINTELLIX), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing vortioxetine in Depressive Disorder, Major, or all of them as a file.
02

Study summary

To evaluate the early onset of efficacy of vortioxetine 17 mg intravenously (IV) and vortioxetine 10 mg/day oral dose regimen versus placebo IV and vortioxetine 10 mg/day oral dose regimen on depressive symptoms

03

Conditions studied

  • Depressive Disorder, Major
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The patient has recurrent Major Depressive Disorder (MDD), diagnosed according to Diagnostic and Statistical Manual for Mental Disorders, 5th Edition (™), classification code (296.3x). The recurrent Major Depressive Episode (MDE) should be confirmed using the Mini-International Neuropsychiatric Interview (MINI).
  • The patient has a Montgomery Åsberg Depression Rating Scale (MADRS) total score ≥30 at both Screening and Baseline Visits.
  • The patient has had the current MDE for ≥3 months

Exclusion criteria

Exclusion Criteria:

  • The patient has any current psychiatric disorder or Axis I disorder (™ criteria), other than MDD, as assessed using the Mini International Neuropsychiatric Interview (MINI).
  • The patient has a current diagnosis of history of manic or hypomanic episode, schizophrenia or any other psychotic disorder, including major depression with psychotic features (DSM-5™ criteria).
  • The patient suffers from personality disorders, intellectual disability, pervasive development disorder, attention deficit/hyperactivity disorder, organic mental disorders, or mental disorders due to a general medical condition (DSM-5™ criteria).
  • The patient has a history of lack of response to previous treatment with vortioxetine (including current episode).

Other Protocol defined inclusion and exclusion criteria may apply

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
55 participants (actual)

Study arms

  • Experimental
    IV vortioxetine

    Drug: Vortioxetine (IV) · Drug: Vortioxetine (tablet)

  • Placebo comparator
    IV placebo

    Other: Placebo (IV) · Drug: Vortioxetine (tablet)

Interventions

  • 17 mg, solution for infusion, administered, over 2 hours as single dose

  • OtherPlacebo (IV)

    Saline: isotonic sodium chloride, administered, over 2 hours as single dose

  • 10 mg, tablets, oral administration once daily for 15 days (open labelled)

06

What researchers measure

Primary outcomes

  1. Change from baseline to Week 1 in MADRS total score

    The Montgomery Åsberg Depression Rating Scale (MADRS) is a depression rating scale consisting of 10 items, each rated 0 (no symptom) to 6 (severe symptom). The 10 items represent the core symptoms of depressive illness. The rating should be based on a clinical interview with the patient, moving from broadly phrased questions about symptoms to more detailed ones, which allow a precise rating of severity, covering the last 7 days. Total score from 0 to 60. The higher the score, the more severe, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.

    Time frame: Baseline to Week 1

Secondary outcomes

  1. Change from baseline to Week 2 in MADRS total score

    The Montgomery Åsberg Depression Rating Scale (MADRS) is a depression rating scale consisting of 10 items, each rated 0 (no symptom) to 6 (severe symptom). The 10 items represent the core symptoms of depressive illness. The rating should be based on a clinical interview with the patient, moving from broadly phrased questions about symptoms to more detailed ones, which allow a precise rating of severity, covering the last 7 days. Total score from 0 to 60. The higher the score, the more severe, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.

    Time frame: Baseline to Week 2

  2. Change from baseline to Day 3 in MADRS total score

    The Montgomery Åsberg Depression Rating Scale (MADRS) is a depression rating scale consisting of 10 items, each rated 0 (no symptom) to 6 (severe symptom). The 10 items represent the core symptoms of depressive illness. The rating should be based on a clinical interview with the patient, moving from broadly phrased questions about symptoms to more detailed ones, which allow a precise rating of severity, covering the last 7 days. Total score from 0 to 60. The higher the score, the more severe, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.

    Time frame: Baseline to Day 3

  3. Change from baseline to Day 1 in MADRS total score

    The Montgomery Åsberg Depression Rating Scale (MADRS) is a depression rating scale consisting of 10 items, each rated 0 (no symptom) to 6 (severe symptom). The 10 items represent the core symptoms of depressive illness. The rating should be based on a clinical interview with the patient, moving from broadly phrased questions about symptoms to more detailed ones, which allow a precise rating of severity, covering the last 7 days. Total score from 0 to 60. The higher the score, the more severe, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.

    Time frame: Baseline to Day 1

  4. Response (defined as a ≥ 50% decrease in MADRS total score from baseline) at Week 1

    Time frame: Week 1

  5. Remission at Week 1 (defined as a MADRS total score ≤ 10)

    Time frame: Week 1

  6. Change from baseline to Week 1 in HADS depression subscale

    The Hospital Anxiety and Depression Scale (HADS) is a patient-rated scale designed to screen for anxiety and depressive states in medical patients. It consists of two sub-scales: the D-scale measures depression and the A-scale measures anxiety. Each sub-scale contains 7 items, and each item is rated from 0 (absent) to 3 (maximum severity). The score of each sub-scale ranges from 0 to 21.

    Time frame: baseline to Week 1

  7. Global clinical impression -Global Improvement

    The Clinical Global Impression - global improvement CGI-I provides the clinician's impression of the patient's improvement (or worsening). The clinician assesses the patient's condition relative to a baseline on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse).

    Time frame: At Week 1

  8. Change from baseline in Global clinical impression -Severity

    The Clinical Global Impression severity of illness (CGI-S) provides the clinician's impression of the patient's current state of mental illness. The clinician uses his or her clinical experience of this patient population to rate the severity of the patient's current mental illness on a 7-point scale ranging from 1 (normal - not at all ill) to 7 (among the most extremely ill patients

    Time frame: Baseline to Week 1

  9. Oral clearance (CL/F)

    Time frame: 2, 8 and 24 hours postdose (day 1) and day 14

  10. Average Plasma Concentration (Cav)

    Time frame: 2, 8 and 24 hours postdose (day 1) and day 14

  11. Change from baseline to Week 1 in HADS anxiety subscale

    The HADS is a patient-rated scale designed to screen for anxiety and depressive states in medical patients. It consists of two sub-scales: the D-scale measures depression and the A-scale measures anxiety. Each sub-scale contains 7 items, and each item is rated from 0 (absent) to 3 (maximum severity). The score of each sub-scale ranges from 0 to 21.

    Time frame: Baseline to Week 1

07

Study locations

7 sites
  • EE1019
    Tallinn, Estonia
  • EE1020
    Tallinn, Estonia
  • FI1040
    Helsinki, Finland
  • FI1041
    Helsinki, Finland
  • FI1030
    Kuopio, Finland
  • FI1009
    Pori, Finland
  • FI1027
    Turku, Finland
08

References and documents

Publications

  • Vieta E, Florea I, Schmidt SN, Areberg J, Ettrup A. Intravenous vortioxetine to accelerate onset of effect in major depressive disorder: a 2-week, randomized, double-blind, placebo-controlled study. Int Clin Psychopharmacol. 2019 Jul;34(4):153-160. doi: 10.1097/YIC.0000000000000271. PubMed 31094901 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2016 to primary completion in Apr 2017, 7 months.

Of 96 industry-sponsored phase 2 interventional studies under Depressive Disorder, Major, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 23. This study's 7 months is below that.

Counting every sponsor, half of 195 studies reached it within 22 months; a quarter within 14 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2016
First posted
Sep 29, 2016
StartActual
Sep 27, 2016
Primary completionActual
Apr 27, 2017
CompletionActual
Apr 27, 2017
Last update
Jun 20, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 20, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02919501
Lead sponsor
H. Lundbeck A/S
Collaborators
Takeda
Responsible party
Sponsor
First posted
Sep 29, 2016
Start date
Sep 27, 2016
Primary completion
Apr 27, 2017
Completion
Apr 27, 2017
Last update
Jun 20, 2018

Study contacts

Email contact via H. Lundbeck A/S
study director · LundbeckClinicalTrials@Lundbeck.com

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vortioxetine

Start the discussion